Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | C1S | P09871 | 1/20 | 0.47 |
| ▸ | CDK4 | P11802 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29852161 | 1.00 | PARP1 (0.57) | PARP1ALDH1A1L3MBTL1TP53LMNA | |
| SCHEMBL17758892 | 0.86 | PARP1 (0.55) | PARP1ALDH1A1L3MBTL1TP53LMNA | |
| SCHEMBL7406706 | 0.85 | MEN1 (0.55) | ALDH1A1L3MBTL1MEN1KMT2AATM | |
| SCHEMBL3931604 | 0.82 | PARP1 (0.44) | PARP1ALDH1A1L3MBTL1LMNAMEN1 | |
| SCHEMBL935497 | 0.82 | PARP1 (0.50) | PARP1ALDH1A1L3MBTL1TP53LMNA | |
| SCHEMBL8366933 | 0.82 | CDK4 (0.52) | PARP1ALDH1A1L3MBTL1TP53LMNA | |
| SCHEMBL4300450 | 0.81 | HPGD (0.69) | PARP1ALDH1A1L3MBTL1LMNAMAPT | |
| SCHEMBL6177291 | 0.80 | KDM1A (0.56) | PARP1ALDH1A1L3MBTL1LMNAMEN1 | |
| SCHEMBL14095771 | 0.80 | ALDH1A1 (0.41) | PARP1ALDH1A1TP53NPSR1CYP1A2 | |
| SCHEMBL7455084 | 0.79 | HSD17B2 (0.47) | PARP1ALDH1A1L3MBTL1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4051667-B1 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | LILAC THERAPEUTICS INC (US) | 2026-01-28 | — | — | EP | disclosed |
| US-12398139-B2 | Modulators of AMPA receptor signaling | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2025-08-26 | — | — | US | disclosed |
| CN-117342963-B | 1, 4-Dicarbonyl compound, and preparation method and application thereof | 上海予君生物科技发展有限公司 | 2025-06-17 | — | — | CN | disclosed |
| EP-3935059-B1 | MODULATORS OF AMPA RECEPTOR SIGNALING | CAMH (CA) | 2025-04-23 | — | — | EP | disclosed |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | LILAC THERAPEUTICS INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | Lilac Therapeutics, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4470538-A2 | HETEROCYCLIC CARBOXYLATE COMPOUNDS AS GLYCOLATE OXIDASE INHIBITORS | Lilac Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024175081-A1 | SHP2 INHIBITOR COMPOUND AND USE THEREOF | 深圳真实生物医药科技有限公司 | 2024-08-29 | — | — | WO | disclosed |
| US-11970499-B1 | Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors | King Faisal University (SA) | 2024-04-30 | — | — | US | disclosed |
| EP-0284076-B1 | Process for preparing (+)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid and related compounds | SYNTEX INC (US) | 1994-06-08 | — | — | EP | disclosed |
| WO-1993021178-A1 | INDOLE DERIVATIVES AS 5-HT1-LIKE AGONISTS | PFIZER LIMITED (GB) | 1993-10-28 | — | — | WO | disclosed |
| EP-0275092-B1 | PROCESS FOR PREPARING (+)-1,2-DIHYDRO-3H-PYRROLO(1,2-A)PYRROLE-1,7-DICARBOXYLATES | SYNTEX (U.S.A.) INC. (US) | 1992-06-03 | — | — | EP | disclosed |
| EP-0284076-A1 | Process for preparing (+)-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid and related compounds | SYNTEX (U.S.A.) INC. (US) | 1988-09-28 | — | — | EP | disclosed |
| EP-0275092-A1 | Process for preparing (+)-1,2-dihydro-3H-pyrrolo(1,2-a)pyrrole-1,7-dicarboxylates | SYNTEX (U.S.A.) INC. (US) | 1988-07-20 | — | — | EP | disclosed |
| EP-0041711-B1 | 6-CHLORO- OR 6-BROMO-1,2-DIHYDRO-3H-PYRROLO(1,2-A)-PYRROLE-1-CARBOXYLIC ACIDS AND DERIVATIVES THEREOF, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1985-04-17 | — | — | EP | disclosed |
| US-4410534-A | 3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors | SYNTEX (U.S.A.) INC. (US) | 1983-10-18 | — | — | US | disclosed |
| US-4344943-A | ANALGESICS, ANTIINFLAMMATORY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1982-08-17 | — | — | US | disclosed |
| EP-0041711-A1 | 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo(1,2-a)-pyrrole-1-carboxylic acids and derivatives thereof, process for their production and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-12-16 | — | — | EP | disclosed |
| US-4089969-A | ANTIINFLAMMATORY, ANALGESIC, ANTIPYRETIC, SMOOTH MUSCLE RELAXANT | SYNTEX (U.S.A.) INC. (US) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | PARP1 462/4885ALDH1A1 2202/4885L3MBTL1 3267/4885 |
| US-12168002-B2 | Heterocyclic carboxylate compounds as glycolate oxidase inhibitors | UGDH, PGD, PNPO | PARP1 2506/4885ALDH1A1 184/4885L3MBTL1 3238/4885 |
| US-11970499-B1 | Pyrazolo[1,5-c]pyrimidine compounds as CK2 inhibitors | CDK2, TK1, CDK1 | PARP1 1349/4885ALDH1A1 4311/4885L3MBTL1 3656/4885 |
| US-12398139-B2 | Modulators of AMPA receptor signaling | GRM2, GRM1, GRIK1 | PARP1 3947/4885ALDH1A1 1697/4885L3MBTL1 3511/4885 |
| US-20250064787-A1 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | GLS, DUOX1, HAO1 | PARP1 1582/4885ALDH1A1 100/4885L3MBTL1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.